Navigation Links
Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging
Date:12/13/2011

ANN ARBOR, Mich., Dec. 13, 2011 /PRNewswire/ -- Molecular Imaging, Inc. (Molecular Imaging), a specialty contract research organization providing multi-modality preclinical in vivo imaging services to pharmaceutical and biotechnology companies, today announced that it has entered into a licensing agreement with Dana-Farber Cancer Institute to access a substantial number of luciferase-enabled cancer cell lines developed at Dana-Farber.  Access to these unique lines dramatically expands Molecular Imaging's ability to apply bioluminescent imaging technology to a broad array of cancer disease models, including expanded capability in various leukemias, multiple myeloma, triple-negative breast cancer, glioma and melanoma. 

Molecular Imaging, Inc. will be collaborating with Andrew Kung, MD, PhD and Scott Armstrong, MD, PhD to further develop and make available these, and other cell lines, to improve the quantification and predictive power of bioluminescent imaging in cancer. Dr. Kung is Director of the Lurie Family Imaging Center at Dana-Farber, is an Associate Professor of Pediatrics at Dana-Farber, Children's Hospital Boston and the Harvard Medical School. Dr. Armstrong is an Associate Professor of Pediatrics at Dana-Farber, Children's Hospital Boston and Harvard Medical School and is co-director of both the Cancer Program/Harvard Stem Cell Institute and Dana-Farber/Harvard Cancer Center's Leukemia program. 

W. R. Leopold, PhD, VP, Research and Development, at Molecular Imaging expressed his enthusiasm with these agreements. "This licensing relationship gives Molecular Imaging access to over 100 additional luc-enabled cell lines, providing the ability to use imaging in a much broader array of cancer disease models, with greater confidence. Access to the knowledge and skills of Drs Kung and Armstrong only makes the opportunity to advance the science of imaging more compelling. We look forward to collaborating with Andrew and Scott in making these cell lines available as part of our services to pharmaceutical and biotechnology companies to enhance R&D decision-making," said Dr. Leopold. 

According to Dr. Kung, he, Dr. Armstrong and Dana-Farber have been working to find the right collaboration to assure the industry has access to these cell lines. "A lot of our effort has gone into developing cell lines that will materially improve the effectiveness of research and development in a wide array of cancers. We believe Molecular Imaging is an excellent partner to accomplish this goal," said Kung.  "Their dedication to preclinical in vivo imaging and their expertise in this area is a perfect complement to the kinds of work being done here to enhance the application of imaging to critical problems in cancer drug discovery." 

Molecular Imaging expects to nearly triple its validated luc-reporter cell line library by end of first quarter 2012. For Molecular Imaging, this expansion in luc-reporter lines complements the incorporation of fluorescence molecular tomography (FMT) into the company's array of imaging modalities. The company will have a number of FMT imaging-validated disease models available by early 2012 to aid in R&D decision-making. Molecular Imaging also offers MRI, micro-CT, micro-PET, bioluminescence and 2D fluorescence to provide the benefits of quantitative anatomical and functional imaging to nearly 100 customers. Since Molecular Imaging provides these services with all imaging modalities in one location, the multiplier benefit of multi-modality imaging is readily available to customers, as well.

Molecular Imaging, Inc. is a specialty contract research organization (CRO) located in Ann Arbor, Michigan. Molecular Imaging employs a wide array of imaging technologies including MRI, micro-CT, micro-PET, FMT, bioluminescence and fluorescence to provide information at anatomical, functional, and molecular levels to enhance decision-making. Complementing Molecular Imaging's imaging expertise is a team of pharmacology experts for optimal integration between disease pharmacology and respective image-based biomarkers and end points. For more information, please visit www.molecularimaging.com or contact Tom Ludlam at (734) 926-4200 or tludlam@molecularimaging.com or Nick Ayers at (201) 970-6586 or nayers@molecularimaging.com.

Dana-Farber Cancer Institute is located at 450 Brookline Avenue, Boston, MA 02215.  For more information, contact Anne Doerr, media relations manager, at 617.632.4090.


'/>"/>
SOURCE Molecular Imaging, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
2. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
4. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
5. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
10. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
11. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
Breaking Medicine News(10 mins):